Literature DB >> 1568280

Selective population chemotherapy among schoolchildren in Beheira governorate: the UNICEF/Arab Republic of Egypt/WHO Schistosomiasis Control Project.

A el Malatawy1, A el Habashy, N Lechine, H Dixon, A Davis, K E Mott.   

Abstract

Selective population chemotherapy using a single dose of praziquantel (40 mg per kg body weight), which was offered to 29,365 schoolchildren in Abu El Matameer and 40,241 in Abo Homos districts, Beheira governorate in the Nile delta, reduced the prevalence of schistosomiasis from 75.4% to 40.9% (reduction of 45.8%) and from 80.5% to 30.8% (reduction of 61.7%), respectively. Of those with only S. mansoni infection, 10.6% before treatment and 1.7% one year later had more than 800 eggs per gram of faeces. The prevalence of S. haematobium in Abu El Matameer was reduced from 35.4% to 7.4% after a single treatment. Infections with both S. mansoni and S. haematobium were reduced by more than 90% after one year. These reductions in prevalence and intensity of schistosomiasis in the face of continuing transmission and water contact augur well for the future role of chemotherapy in control programmes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568280      PMCID: PMC2393350     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

Review 1.  The relevance of schistosomiasis for public health.

Authors:  B Gryseels
Journal:  Trop Med Parasitol       Date:  1989-06

2.  Two-year follow-up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel.

Authors:  B Gryseels; L Nkulikyinka
Journal:  Trans R Soc Trop Med Hyg       Date:  1989 Mar-Apr       Impact factor: 2.184

3.  Evaluation of UNICEF/Arab Republic of Egypt/WHO schistosomiasis Control Project in Beheira Governorate.

Authors:  H C Spencer; E Ruiz-Tibén; N S Mansour; B L Cline
Journal:  Am J Trop Med Hyg       Date:  1990-05       Impact factor: 2.345

4.  Treatment with praziquantel of schoolchildren with concurrent Schistosoma mansoni and S. haematobium infections in Gezira, Sudan.

Authors:  M W Kardaman; A Fenwick; A B el Igail; M el Tayeb; A A Daffalla; H G Dixon
Journal:  J Trop Med Hyg       Date:  1985-04

5.  The epidemiology of Schistosoma haematobium and S. mansoni infections in the Egypt-49 project area. 1. Sampling techniques and procedures for measuring the prevalence of bilharziasis.

Authors:  M Farooq; J Nielsen
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

6.  Changing pattern of schistosomiasis in Egypt 1935--79.

Authors:  M F Abdel-Wahab; G T Strickland; A El-Sahly; N El-Kady; S Zakaria; L Ahmed
Journal:  Lancet       Date:  1979-08-04       Impact factor: 79.321

  6 in total
  5 in total

1.  The global status of schistosomiasis and its control.

Authors:  L Chitsulo; D Engels; A Montresor; L Savioli
Journal:  Acta Trop       Date:  2000-10-23       Impact factor: 3.112

2.  Persistent Colonic Schistosomiasis among Symptomatic Rural Inhabitants in the Egyptian Nile Delta.

Authors:  Mohamed Hussien Ahmed; Mohamed H Emara; Amr Asem Elfert; Aymen M El-Saka; Asem Ahmed Elfert; Sherief Abd-Elsalam; Mohamed Yousef
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-05-01       Impact factor: 2.576

3.  Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.

Authors:  C H King; E M Muchiri; J H Ouma
Journal:  Emerg Infect Dis       Date:  2000 Nov-Dec       Impact factor: 6.883

Review 4.  Hepatic and intestinal schistosomiasis: review.

Authors:  Tamer Elbaz; Gamal Esmat
Journal:  J Adv Res       Date:  2013-01-11       Impact factor: 10.479

Review 5.  Integration of schistosomiasis control activities within the primary health care system: a critical review.

Authors:  Paul Bizimana; Giuseppina Ortu; Jean-Pierre Van Geertruyden; Frédéric Nsabiyumva; Audace Nkeshimana; Elvis Muhimpundu; Katja Polman
Journal:  Parasit Vectors       Date:  2019-08-07       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.